Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Voyager continues to assess its planned cash needs both during the current period and in future periods. We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics reports Q3 EPS (16c), consensus (45c)
- VYGR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Voyager Therapeutics selloff on UCB news ‘excessive,’ says Leerink
- Voyager Therapeutics initiated with an Outperform at Leerink
- Voyager advances Neurocrine collaboration, selects third gene therapy candidate
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
